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Abstract
Certain bacterial adhesins appear to promote a pathogen’s extracellular lifestyle rather than its entry into host cells.
However, little is known about the stimuli elicited upon such pathogen host-cell interactions. Here, we report that type IV
pili (Tfp)-producing Neisseria gonorrhoeae (P
+GC) induces an immediate recruitment of caveolin-1 (Cav1) in the host cell,
which subsequently prevents bacterial internalization by triggering cytoskeletal rearrangements via downstream
phosphotyrosine signaling. A broad and unbiased analysis of potential interaction partners for tyrosine-phosphorylated
Cav1 revealed a direct interaction with the Rho-family guanine nucleotide exchange factor Vav2. Both Vav2 and its
substrate, the small GTPase RhoA, were found to play a direct role in the Cav1-mediated prevention of bacterial uptake. Our
findings, which have been extended to enteropathogenic Escherichia coli, highlight how Tfp-producing bacteria avoid host
cell uptake. Further, our data establish a mechanistic link between Cav1 phosphorylation and pathogen-induced
cytoskeleton reorganization and advance our understanding of caveolin function.
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Introduction
The primarily extracellular obligate human pathogen Neisseria
gonorrhoeae (P
+GC) is the causative agent of the sexually transmitted
disease gonorrhoea, affecting over 60 million people every year
worldwide [1]. It is a type IV pili (Tfp)-producing bacteria that
colonizes mucosal epithelia of the human urogenital tract [2]. Tfp
are proteinaceous filaments that play a crucial role in pathogenesis
by mediating the initial attachment to host cell receptors and are
expressed on the surface of a variety of bacterial pathogens such as
Gram-negative N. meningitidis, Pseudomonas aeruginosa, and enteropatho-
genic E. coli (EPEC) as well as Gram-positive Streptococcus sanguis and
Clostridium perfringens [3]. A growing body of evidence suggests that
adhesins such as Tfp are key pathogenesis factors facilitating not
only attachment but soliciting the necessary host cell cytoskeletal
rearrangements and signaling cascades that promote an extracel-
lular lifestyle [4]. Tfp-expression and cytoskeletal remodeling allows
N. meningitidis to resist shear stress possibly encountered in the
bloodstream [5], and mechanical forces generated by pilus
retraction of P
+GC lead to cytoprotection [6]. However, details of
the elicited signaling cascades within the host cell upon attachment
of Neisseria remain patchy and require clarification.
The early stages of infection with P
+GC are characterized by
Tfp-mediated attachment to host cells [7]. This is followed by
retraction of pili in a force-generating depolymerization process
[8] and formation of microcolonies on the surface of host epithelial
cells [2]. Cortical actin and various signal transducing proteins are
then recruited to the site of bacterial attachment [9]. As infection
proceeds, the phase-variable opacity associated (Opa) proteins are
expressed, allowing occasional entry and transcytosis of individual
bacteria through epithelial cells to reach underlying tissues [10].
Several signaling proteins that are recruited to P
+GC microcol-
onies have also been found to be associated with lipid rafts and
caveolae, cholesterol-enriched microdomains of cell membranes
[11], suggesting that these or associated proteins play an essential
role in this initial infection step. The major structural protein of
PLoS Biology | www.plosbiology.org 1 August 2010 | Volume 8 | Issue 8 | e1000457plasma membrane caveolae, caveolin-1 (Cav1), is also known to
localize to subcellular compartments and to the cytoplasm [12].
Cav1 has been shown to inhibit signal transduction by binding to
numerous target proteins with its scaffolding domain [12], but it
can also promote signaling events through phosphorylation on
tyrosine 14 (Tyr14) [13,14]. We speculated therefore that Cav1
could play an important role during P
+GC infection. Here we
provide evidence that during the early stages of infection, P
+GC
triggers a phosphotyrosine-dependent Cav1-Vav2-RhoA signaling
cascade that elicits cytoskeletal rearrangements and effectively
impedes bacterial uptake into host cells.
Results/Discussion
To assess the role of Cav1 in the Tfp-mediated binding of P
+GC to
host cells,we began by monitoring the cellular localization of Cav1 in
ME-180 cells, a human epidermoid carcinoma cell line, immediately
following infection. We found that endogenous Cav1 localized close
to P
+GC microcolonies after 2 h of infection (Figure 1A). Using live-
cell imaging, we likewise observed a substantial accumulation of
Cav1-GFP at sites of bacterial infection, which was induced even by
single diplococci and within seconds after P
+GC attachment
(Figure 1B, lower panel). Cav1-GFP recruitment occurred through-
out the early stages of infection, resulting ultimately in a conspicuous
accumulation of the protein (Figure 1B, upper panel and Video S1).
By contrast, using a non-piliated isogenic GC strain (P
2 Opa57
+GC
is a non-piliated isogenic strain of P
+GC that produces an Opa57
adhesinspecificforCEACAMreceptors),wefoundnorecruitmentof
endogenous Cav1 in ME-180 cells (Figure S1A). Interestingly, despite
the observed recruitment of Cav1 after P
+GC infection, microarray
and Western blot analysis failed to detect any increase in Cav1
expression (unpublished data). This rather points to a cellular Cav1
reorganization leading to Cav1-accumulation than de novo synthesis.
The functional role of Cav1 in bacterial infection was then
explored by downregulating Cav1 levels in ME-180 cells using RNA
interference (RNAi). Reduced Cav1 levels resulted in efficient
internalization of P
+GC by ME-180 cells, as demonstrated by
gentamicin protection assays (Figure 1C) and confocal microscopy
(Figure 1D). Next, we turned to the human gastric carcinoma cell line
AGS, which, like many other malignant cell lines, is devoid of
detectable levels of Cav1 [15]. Stably transfected cell lines, AGS-
Mockand AGS-Cav1,wereinfected with P
+GCfor 2 h and bacterial
uptake was monitored by gentamicin protection assay. In contrast to
mock-transfected cells, Cav1-expressing AGS cells inhibited P
+GC
internalization (Figure 1C). As before, siRNA-mediated down-
regulation of Cav1 in AGS-Cav1 cells restored bacterial uptake
(Figure 1C). The total number of cell-associated bacteria was similar
intheAGSandME-180cellsandwasunaffectedbyCav1expression.
In addition, inhibition of bacterial uptake was Tfp-specific, as Opa-
mediated bacterial uptake remained unaltered by Cav1 expression
(Figure S1B). Finally, bacterial uptake was independent of pilus
retraction, as indicated by the use of an isogenic, non-retractile PilT-
deficient GC mutant (Figure S1C). Interestingly, in Cav1-negative
AGS cells the observed epithelial cell entry resulted in a drastic
decrease over time in the viability of internalized bacteria (Figure 1E).
Taken together, these results demonstrate that Cav1 plays a pivotal
role in preventing internalization of P
+GCby host epithelial cells, thus
promoting bacterial survival.
To broaden our findings, we also investigated Cav1 recruitment in
EPEC infection, as initial adherence of EPEC to intestinal epithelial
cells is conducted by type IV bundle-forming pili [16]. To avoid
super-imposition with the actin-recruiting function of the EPEC type
III secretion system (TTSS; [17]), we used a TTSS deficient mutant
that still expressed Tfp. Interestingly, we found that the infection of
epithelial cells by EPEC also induced an accumulation of Cav1
beneath the bacteria, similar to our observations with P
+GC (Figure
S2A). Most importantly, Tfp-producing EPEC entered Cav1
deficient AGS cells more rapidly compared to cells producing Cav1
(Figure S2B). This pronounced effect was even observed in the
presence of the EPEC TTSS, thus emphasizing a generalized role of
Cav1 in blocking cell entry of Tfp-producing bacteria. Together, our
data suggest that Cav1 accumulation is a Tfp-specific and immediate
cellular response to bacterial attachment that occurs throughout the
early stages of infection.
Cav1 has also been shown to localize to non-caveolar cellular
regions, where it participates in transport of signaling proteins via
phosphorylation on Tyr14 [18–20]. We hypothesized that Cav1
recruited to P
+GC microcolonies localizes outside caveolae and
plays a role in protein trafficking or signaling. To address this
question, we mapped the location of Cav1 in infected host cells
using 3D-reconstruction of confocal images and immunogold
staining. We found that Cav1 accumulates in the vicinity of P
+GC
but not directly at the plasma membrane (Figure 2A and Figure
S3). Analysis of horizontal sections of confocal image stacks
revealed F-actin structures in infected cells localized between the
plasma membrane and endogenous Cav1 (Figure 2B). This is
consistent with previous observations on the assembly of F-actin
structures in epithelial cells following the attachment of P
+GC [9],
corroborating an association between F-actin and Cav1. Indeed,
treatment of ME-180 cells with either cytochalasin D (Cyt D) or
latrunculin A (Lat A), which disrupt actin filaments, prevented
Cav1 accumulation (Figure S4A) and induced bacterial internal-
ization as shown by confocal imaging (unpublished data) and
gentamicin protection assays (Figure S4B). Thus, both recruitment
of Cav1 and inhibition of bacterial internalization require a
functional actin cytoskeleton.
Cav1 has previously been reported to bind cytoskeletal
components such as the actin-crosslinking protein filamin and
intermediate filaments [21,22]. Moreover, relocation of Cav1 to
Author Summary
Like many bacterial pathogens, successful attachment of
Neisseria gonorrhoeae—the causative agent of the sexually
transmitted disease gonorrhoea—to its host cells depends
on specialized structures on the bacterial surface called
type IV pili (Tfp). Pathogen attachment induces changes
within host cells that may facilitate and promote infection.
In this study, we identify some of the earliest cellular
signals elicited by N. gonorrhoeae during infection, which,
in this case, prevent the organism from entering the cell
precociously. After attachment to host cells the bacteria
form microcolonies on the cell surface. Underneath these
microcolonies, so-called cortical plaques form within the
host cell—these contain the cytoskeleton protein actin
and a range of signaling proteins. We show that N.
gonorrhoeae recruits a host cell protein called caveolin-1 to
the cell membrane where the bacteria are attached; here,
caveloin-1 effectively impedes uptake of the bacteria by
activating a signaling cascade that involves its phosphor-
ylation on a tyrosine residue and subsequent interactions
with proteins that regulate the cytoskeleton. Thus, these
proteins play a pivotal role in maintaining N. gonorrhoeae
in the extracellular milieu. By extrapolating our findings to
another Tfp-producing bacterium, the enteropathogenic
Escherichia coli, we argue that the establishment and
maintenance of this extracellular state benefits certain
pathogens by giving them time to express proteins
required for subsequent steps of infection.
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along cytoskeletal structures and is dependent on the presence of
Tyr14 [23]. To determine if the Cav1-cytoskeleton association
observed here was dependent on Tyr14 of Cav1, we purified the
cytoskeletal fraction from AGS cells that had been transfected
either with an epitope-tagged version of wild-type Cav1 (Cav1-
HA) or with a phosphorylation-defective mutant (Y14F-Cav1-
HA). Similar to endogenous Cav1 in ME-180 cells, Cav1-HA was
completely recovered from the cytoskeletal fraction of transfected
AGS cells, whereas only 45% of the total Y14F-Cav1-HA was
Figure 1. Expression and recruitment of Cav1 prevents internalization of P
+GC by host cells. (A) Recruitment of endogenous Cav1 (white,
middle panel) to attached P
+GC (green, right panel) in ME-180 cells 2 h post-infection. (B) Excerpts of Movie 1: Cav1-GFP (green) is recruited within
seconds to microcolonies and individually attached P
+GC (red) in ME-180 cells (lower panels). Recruitment continues as infection proceeds (upper
panels). Attached P
+GC are indicated by arrows. (C) Knockdown of Cav1 in ME-180 cells and in Cav1 expressing AGS cells (AGS-Cav1) results in P
+GC
internalization. Cav1 expression was downregulated by transfection of two different siRNAs (Cav1-I or Cav1-II) in ME-180 and AGS-Cav1 cells using
lamin A/C as a control siRNA. Gentamicin protection assays were performed 2 h post-infection (upper panel). Experiments were performed in
triplicate. Data are mean 6 standard deviation. Cav1 knockdown efficiency was confirmed by Western blot analysis (lower panel). (D) shRNA-
mediated downregulation of Cav1 in ME-180 cells results in P
+GC internalization. Intracellular bacteria (red) are detected in ME-180 shCav1 cells
(upper right panels), whereas only extracellular bacteria (yellow-green) are detected in ME-180 shLuciferase control cells (upper left panels). Efficiency
of Cav1 knockdown in ME-180 cells after lentiviral transduction of Luciferase (control) or Cav1 shRNA constructs (lower panel). Scale bar: 20 mm. (E)
Numbers of viable intracellular P
+GC in AGS cells decrease rapidly over time. Infected cells were initially treated with gentamicin for 2 h, then further
incubated in gentamicin and serum-free medium and lysed at indicated time points. Experiments were performed in triplicate. Data are mean 6
standard deviation.
doi:10.1371/journal.pbio.1000457.g001
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+GC
infection no significant differences in the Cav1-cytoskeleton
association were observed expressing either Cav1 construct
(unpublished data). Thus, it is likely that phosphorylation of
Cav1 on Tyr14 promotes its association with the cytoskeleton.
To understand the importance of Cav1 phosphorylation during
infection with P
+GC, we monitored the phosphorylation status of
Cav1 during infection (2 h) of serum starved ME-180 cells. In
addition, we blocked Src kinases and Abl kinases using chemical
inhibitors previously reported to phosphorylate Cav1 [24,25]. The
Src family kinase inhibitor PP2 [26] and Abl tyrosine kinase
inhibitor STI571/Imatinib [27] were added (10 mM each),
individually and in combination, 1 h prior to infection. Western
blot analysis of phospho-Tyr14-Cav1 levels (Figure 2D, upper
Figure 2. Tyrosine-phosphorylation of Cav1 is required for Cav1 association with the cytoskeleton and to prevent internalization of
P
+GC by host cells. (A) 3D reconstruction of confocal images depicting Cav1-GFP (green) recruitment in the host cell 2 h post-infection with P
+GC
(red). Gaps between P
+GC and Cav1 are indicated by arrows. (B) Horizontal and vertical confocal image sections show F-actin (red) localization
between bacteria (blue) and endogenous Cav1 (green) in infected ME-180 cells. Scale bar: 10 mm. (C) Interaction of Cav1 with cytoskeletal
components depends on Cav1 phosphorylation. Fractionation of transfected AGS cells reveals a strong association of wild-type Cav1 (Cav1-HA), but
not the phosphorylation-deficient mutant (Y14F-Cav1-HA), with cytoskeletal components (lower panel, red marking). Quantification of band
intensities revealed a marked decrease (55%) in the association of Y14F-Cav1-HA with the cytoskeleton as compared to Cav1-HA. Endogenous Cav1
also associates with cytoskeletal components in ME-180 cells (lower panel). Cytokeratin 8 serves as a control for the correct localization of
cytoskeleton-associated proteins (upper panel). 14-3-3b serves as a control for complete removal of cytoplasm-associated proteins from the
cytoskeletal components fraction (middle panel). Full lysate rows serve as loading and protein expression controls. (D) Cav1 phosphorylation during
P
+GC infection depends on Abl and Src kinases. Western blot analysis of phospho-Tyr14-Cav1 levels (upper panels) and quantification of data (lower
panel) show elevated Cav1 phosphorylation starting 5 min after infection. Stimulation of phosphorylation by P
+GC is reduced in Src-inhibitor PP2 and
Abl-inhibitor STI571-treated cells (both 10 mM). (E) Recruitment of phospho-Tyr14-Cav1 (green, middle panel, white arrows) to attached P
+GC (red,
right panel) in ME-180 cells 2 h post-infection. Scale bar: 10 mm. (F) Bacterial uptake is observed in Cav1-negative, AGS cells (left panel) but not in
wild-type Cav1-transfected AGS cells (middle panel). By contrast, transfection of the phosphorylation-deficient mutant, Y14F-Cav1, does not impede
bacterial uptake (right panel). Bacterial infection did not change the localization of Y14F-Cav1 in cells (right panel). Intracellular bacteria appear in red,
extracellular bacteria in yellow-green, and Cav1 in blue. Cellular borders are represented as white outlines. Scale bars: 20 mm. Data in A–F are
representative of three independent experiments.
doi:10.1371/journal.pbio.1000457.g002
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P
+GC were able to elicit Cav1 phosphorylation at Tyr14. In
control-treated ME-180 cells, Cav1 phosphorylation levels were
increased 1.5-fold after 5 min of infection. Phosphorylation levels
then reached a plateau phase before rising again after 30 min,
increasing up to 4-fold after 90 min of infection. In accordance
with previous reports [24,25], this phosphorylation depended on
active Src- and Abl-kinases. Compared to untreated control cells,
stimulation of phosphorylation by P
+GC in PP2- and STI571-
treated cells was markedly reduced during the whole infection
period. Strikingly, ME-180 cells treated with both inhibitors
exhibited minimal levels of phosphorylation and stimulation by
P
+GC was negligible. Next, we determined the cellular localization
of phospho-Tyr14-Cav1 using confocal imaging (Figure 2E).
Despite the low levels of immunostained phosphorylated Cav1,
phospho-Tyr14-Cav1 was detected in the vicinity of attached
P
+GC, as observed previously with non-phosphorylated Cav1,
suggesting a direct link between P
+GC infection and Cav1
phosphorylation. Hence, we infected AGS cells expressing either
wild-type Cav1-HA or Y14F-Cav1-HA with P
+GC. In contrast to
wild-type Cav1, Y14F-Cav1 was not recruited to bacterial
attachment sites and did not impede internalization (Figure 2F),
strongly suggesting that Cav1 phosphorylation at Tyr14 is induced
or enhanced by P
+GC, enabling Cav1 recruitment, Cav1-
mediated prevention of bacterial uptake, and a strong association
of Cav1 with the cytoskeleton. Taken together, our data suggest
that Cav1 phosphorylation plays a role in downstream signaling,
linking Cav1 with cytoskeletal rearrangements.
To identify signaling proteins that could interact with Cav1
upon phosphorylation at Tyr14, we synthesized two fluorescently
labeled peptides with sequences corresponding to residues 5-22 of
Cav1, one phosphorylated on Tyr14 and the other not
phosphorylated. We then used these peptides to probe protein
microarrays comprising virtually every Src homology 2 (SH2) and
phosphotyrosine binding (PTB) domain encoded in the human
genome, as previously described [28]. In order to obtain
quantitative information, we probed the arrays, in duplicate, with
eight concentrations of each peptide, ranging from 10 nM to
5 mM. We then fit the resulting fluorescence data to an equation
that describes saturation binding [28], enabling us to obtain
equilibrium dissociation constants (KDs) for the binding of each
peptide to each recombinant domain (Figure 3A). Previous studies
with other phosphopeptides have shown that .90% of the SH2
and PTB domains on these arrays are active [28] and hence non-
interactions should be viewed as reliable information as well.
In total, the arrays highlighted six SH2 domains that recognized
the Cav1 phosphopeptide with high affinity (KD ,2 mM): Abl2,
Vav2, Phospholipase Cc1 (PLCc1), SH2D3C, Grb10, and Abl1.
Although strong interactions with the SH2 domain of Abl2 are
frequently observed (this is a particularly promiscuous domain), we
were intrigued by the high affinity interaction with the SH2
domain of RhoA GEF Vav2 (KD=220 nM). To investigate the
physiological relevance of this biophysical interaction, we
performed the following biochemical experiments: First, we
incubated biotin-labeled peptides with sequences corresponding
to residues 7–21 of Cav1, one phosphorylated on Tyr14 and the
other not phosphorylated, with cellular lysates derived from ME-
180 cells and precipitated the peptides with streptavidin-coated
beads. Consistent with the microarray data, Vav2 co-purified
exclusively with the phosphorylated peptide (Figure 3B). More-
over, 40% more Vav2 was recovered from infected cell lysates
than from uninfected cells. Similarly, PLCc1, another important
binding partner identified by the protein microarray, showed a
vastly increased binding affinity to the phosphorylated peptide.
However, levels of PLCc1 were similar in both lysate types. Next,
we immunoprecipitated full-length, endogenous Cav1 protein
from either untreated ME-180 cells or from cells that had been
pretreated with the tyrosine phosphatase inhibitor pervanadate to
trigger elevated levels of Cav1 phosphorylation. Western blot
analysis revealed binding between Vav2 and full-length Cav1 in
pervanadate-treated cells (Figure 3C). To better understand the
molecular mechanism of the observed phospho-Tyr14-Cav1–
Vav2 interaction we expressed different Vav2 constructs (Figure
S5) in ME-180 cells and immunoprecipitated them using
antibodies against the respective tags [29,30]. First, we expressed
the full-length Vav2 coupled with GFP in pervanadate- and
control-treated cells. We were then able to precipitate GFP-Vav2
and control GFP from transfected cells using a GFP antibody;
however, phospho-Tyr14-Cav1 co-precipitated exclusively with
pervanadate-treated GFP-Vav2 expressing cells (Figure 3D). This
further demonstrated the phospho-specificity of the phospho-
Tyr14-Cav1–Vav2 protein-protein interaction.
Since only the SH2 domain of the Vav2 protein had been
spotted on the protein microarray, we assumed the Vav2-Cav1
interaction was SH2-specific. To verify this, we expressed
truncated Vav2 coupled to FLAG in pervanadate- and control-
treated cells. Truncated Vav2 consists solely of the C-terminal
SH3-SH2-SH3 domains of the protein (Figure S5). Similar to full-
length Vav2, we were able to precipitate truncated Vav2 from
transfected cells using a FLAG antibody. Again, phospho-Tyr14-
Cav1 co-precipitated exclusively with pervanadate-treated, trun-
cated Vav2 expressing cells (Figure 3E), demonstrating the
relevance of the remaining Vav2 domains for the observed
phospho-Tyr14-Cav1–Vav2 interaction. Taken together, these
results identify the RhoA GEF Vav2 as a novel interaction partner
of tyrosine-phosphorylated Cav1.
Next, we assessed the role of Vav2 and PLCc1i nP
+GC
infection by knocking down their function in ME-180 cells using
RNAi. Confocal microscopy revealed that, as with Cav1, reducing
Vav2 levels using siRNA resulted in efficient internalization of
P
+GC by ME-180 cells (Figure 4A). By contrast, shRNA-mediated
downregulation of PLCc1 in ME-180 cells did not result in P
+GC
internalization (Figure S6A). This shows that Vav2 plays a role in
preventing bacterial uptake, possibly by participating in cytoskel-
etal reorganization through its function as a GEF for the Rho/Rac
family of GTPases. Alternatively, Vav2 could function in a
manner independent of its GEF activity simply by physically
linking signaling molecules to the actin cytoskeleton [31]. To test
for the involvement of RhoA in impeding bacterial internalization,
we treated ME-180 cells with low concentrations of the Rho-
specific inhibitor CT04, a cell permeable form of the C3
transferase from Clostridium botulinum, and subsequently infected
the cells with P
+GC. Interestingly, treatment with CT04 led to a
strong uptake of bacteria (Figure 4B). Since Vav2 also activates
Rac1 [32], we also tested the relevance of Rac1 for P
+GC
internalization. ME-180 cells were treated with the Rac1-specific
chemical inhibitor NSC23766 [33] and then infected with P
+GC.
In contrast to Rho inhibition, treatment with NSC23766 did not
affect bacterial entry (Figure 4C). These results were also
confirmed in ME-180 and HeLa epithelial cells using different
inhibitor concentrations (Table S1). Partial siRNA-mediated
knockdown of RhoA further demonstrated the relevance of this
small GTPase in impeding cellular uptake of P
+GC. Interestingly,
downregulation of other small GTPases such as Cdc42 and Rac1
did not enhance P
+GC internalization (Figure S6B and Table S2).
Together, these findings highlight the importance of RhoA in
preventing bacterial entry, probably by forming a cytoskeletal
barrier.
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activation, we compared RhoA activation in control ME-180 cells
expressing a luciferase shRNA with Cav1 shRNA knockdown cells
in response to infection with P
+GC. Control cells showed a strong
increase in the levels of the GTP-bound state of RhoA within the
first 5 min of infection, followed by a decline to basal levels over
the next 10 min. By contrast, Cav1 knockdown cells did not
activate RhoA throughout the early stages of infection (p,0.05,
Figure 5A). These data support a model in which a signaling
cascade involving Cav1, Vav2, and RhoA act to inhibit the
internalization of P
+GC by host cells. Finally, to delineate the
sequence of the Cav1-Vav2-RhoA signaling cascade, we infected
both Vav2-knockdown ME-180 cells and CT04-treated ME-180
cells with P
+GC and monitored the recruitment of Cav1 by
confocal microscopy (Figure 5B). Cav1 recruitment was not
affected by either treatment, indicating that Cav1 lies upstream of
Vav2 and RhoA. Taken together, our data strongly suggest that
P
+GC infection induces a Cav1-Vav2-RhoA signaling cascade in
host cells. Phosphotyrosine-dependent Cav1 recruitment to sites of
bacterial attachment induces the recruitment of Vav2 and RhoA
in response to infection, which functions to prevent bacterial
internalization, probably via RhoA-dependent cytoskeletal rear-
rangements.
Our findings highlight a compelling anti-invasive strategy of
pathogenic bacteria, uncover Vav2 as a novel Cav1 signaling
partner, and suggest ways in which tyrosine-phosphorylated-Cav1
could mediate cytoskeletal rearrangements. In addition to
identifying Vav2 as a Cav1 interaction partner, our protein
Figure 3. Phospho-Tyr14-Cav1 interacts strongly with the Rho-GEF Vav2. (A) A comprehensive, quantitative screen using microarrays of
recombinant human SH2 and PTB domains reveals Tyr14-phosphorylation-dependent binding of Cav1 to several SH2-domain-containing proteins.
The RhoA GEF Vav2 shows a high-affinity interaction (KD of 222 nM) with the Tyr14-Cav1 phosphopeptide. The red circle represents the Tyr14-Cav1
phosphopeptide (18 amino acids); the purple circle represents the corresponding non-phosphorylated peptide; green and blue circles represent SH2
and PTB domains, respectively. Green or blue circles outside the rectangle represent tandem domains. The color of lines connecting peptides to
domains indicates strength of observed interactions (see legend). KD values for each hit are provided on the legend. (B) Vav2 and PLCc1 co-
precipitate with biotin-labeled Tyr14-Cav1 phosphopeptide. Western blot analysis of streptavidin precipitates of infected and uninfected ME-180 cells
using biotin-labeled phosphorylated and non-phosphorylated Tyr14-Cav1 peptides as baits. Vav2 and PLCc1 are found mainly in precipitates of the
phosphorylated peptide. Levels of precipitated Vav2, but not PLCc1, increase (by 40%) upon infection with P
+GC. (C) Co-immunoprecipitation
demonstrates increased protein-protein interaction of Cav1 and Vav2 after cell treatment with the phosphotyrosine phosphatase (PTP)-inhibitor
pervanadate. Western blot analysis of immunoprecipitates of ME-180 cells using full-length Cav1 protein as bait. Cav1 was immunoprecipitated from
untreated (2) and pervanadate-treated cells (+). Precipitates were probed for Cav1, phospho-Tyr14-Cav1, and Vav2. Tyrosine-phosphorylated Cav1
was precipitated exclusively from pervanadate-treated lysates. Levels of co-precipitated Vav2 are markedly increased in pervanadate-treated lysates.
(D) GFP-Vav2 and Cav1 interact exclusively after cell treatment with pervanadate. Western blot analysis of total cell lysates (upper panels) and
immunoprecipitates (lower panels) using heterologously expressed GFP-Vav2 (construct depicted in Figure S5, upper panel) or GFP protein as baits.
Lysates were probed for GFP, Cav1, and phospho-Tyr14-Cav1, respectively. GFP-Vav2 and GFP were immunoprecipitated from untreated (2) and
pervanadate-treated cells (+) using a GFP antibody. Precipitates were probed for GFP and phospho-Tyr14-Cav1. Phosphorylated Cav1 was recovered
exclusively from pervanadate-treated lysates of GFP-Vav2 expressing cells. (E) Truncated Vav2 and Cav1 interact exclusively after cell treatment with
pervanadate. Western blot analysis of ME-180 cell lysates (upper panels) and immunoprecipitates (lower panels) using heterologously expressed
truncated Vav2 (construct depicted in Figure S5, lower panel) or FLAG-tag peptide as baits. Truncated Vav2 only possesses the C-terminal SH3-SH2-
SH3 domains of Vav2. Using a FLAG antibody, truncated Vav2 was immunoprecipitated from untreated (2) and pervanadate-treated cells (+).
Phosphorylated Cav1 was recovered exclusively from lysates of pervanadate-treated truncated Vav2 expressing cells. Data in A–E are representative
of three independent experiments.
doi:10.1371/journal.pbio.1000457.g003
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implicated in modulating the cytoskeleton through small GTPases:
SH2D3C is an integrin-associated signaling pathway component,
proposed to regulate the actin cytoskeleton via its GEF-like
domain which binds Ras family GTPases [34]; PLCc1 exhibits
mitogenic activity by acting as a GEF for the small GTPase PIKE
(phosphatidylinositol-3-OH kinase (PI(3)K) enhancer) [35] and is
also capable of directly activating Rac1 [36]; Grb10 putatively
binds small GTPases of the Ras superfamily [37]; and the Abl
kinases are known to link various cell surface receptors to signaling
pathways involved in cytoskeletal reorganization and to regulate
the activation of Rac and Rho GTPases [38,39]. It remains to be
determined if these additional proteins play a role in Cav1-
mediated signaling.
Recently, Cav1 has been demonstrated to interact with RhoA
and Rho-associated kinase 1 (ROCK1) to promote Rho activation
through inhibition of the Src-p190RhoGAP pathway. Cav1 has
also been shown to serve as a target of ROCK1 signaling,
indicating the presence of a positive feedback loop [40–42].
Furthermore, phospho-Tyr14-Cav1 orders microdomains within
focal adhesions and stabilizes focal adhesion-associated kinase
[43,44]. Here, we report a direct link between RhoA activation
Figure 4. Vav2 and RhoA prevent internalization of P
+GC by host cells. (A) Knockdown of Vav2 levels in ME-180 cells using siRNA results in
P
+GC internalization. Intracellular bacteria (red) are detected in siVav2-treated ME-180 cells (upper right panels), whereas only extracellular bacteria
(yellow-green) are detected in siLuciferase-treated control cells (upper left panels). Efficiency of Vav2 knockdown in ME-180 cells after siRNA
treatment (lower panel). Scale bar: 20 mm. (B) Treatment of ME-180 cells with the membrane-permeable Rho inhibitor CT04 results in P
+GC
internalization. Intracellular bacteria (red) are detected in CT04-treated ME-180 cells (right panels), whereas only extracellular bacteria (yellow-green)
are detected in control-treated ME-180 cells (left panels). Scale bar: 20 mm. (C) Treatment of ME-180 cells with the Rac1 inhibitor NSC23766 does not
result in P
+GC internalization. Only extracellular bacteria (yellow-green) are detected in 100 mM NSC23766-treated ME-180 cells (right panel) and
control-treated ME-180 cells (left panel). Scale bar: 20 mm. Data in A–C are representative of three independent experiments.
doi:10.1371/journal.pbio.1000457.g004
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Phosphorylation of Cav1 on Tyr14 may serve as a crucial switch
between the activated and inactivated state of RhoA. Thus, the
direct interaction of tyrosine-phosphorylated Cav1 with Vav2
might support increased activation of RhoA in cellular compart-
ments where tyrosine-phosphorylated Cav1 accumulates, such as
focal adhesions or at sites of P
+GC attachment.
Together, our data reveal an immediate early anti-invasive
activity of P
+GC, dependent on tyrosine-phosphorylated Cav1
host-cell signaling, that facilitates the establishment and mainte-
nance of this pathogen’s extracellular niche. This process,
triggered by Vav2-mediated activation of RhoA, elicits cytoskeletal
rearrangements that may function as a physical barrier to prevent
internalization of attached bacteria. Cav1 is known to participate
in protein trafficking [18], and we have observed a drastic,
instantaneous, and RhoA-independent recruitment of Cav1 at
sites of P
+GC attachment. Thus, Cav1 is the presumptive central
element of the identified Cav1-Vav2-RhoA signaling cascade,
playing a crucial role in the localization of its signaling partners to
the site of infection. The resulting prevention of premature uptake
seems to be beneficial for these bacteria as P
+GC are rapidly killed
inside host cells. P
+GC, and probably other Tfp-producing
bacteria including EPEC, could use this initial extracellular phase
to adapt and prepare for the subsequent steps of infection. For
example, GC employ variation of the Opa invasins to prepare
individual bacteria for deliberate cell entry [10] and transcytosis
[45]. EPEC, on the other hand, may use their Tfp as an
immediate block to cell entry even before the TTSS is placed or
used in delivering its anti-invasive effectors [46]. Taken together,
this Tfp-triggered mechanism extends our understanding of how
P
+GC use pili to elicit cytoprotective effects and modulate the host
cell for their own benefit, as described previously [5,6]. By
investigating P
+GC colonizing its host, we have exploited these
bacteria as a tool to identify an anti-invasive bacterial strategy as
well as a novel Cav1-dependent signaling cascade leading to RhoA
activation.
Methods
Cell Lines and Bacterial Infection
The human cervix carcinoma cell line ME-180 (ATCC HTB33)
was grown in McCoy’s 5A medium (Gibco-Invitrogen, Carlsbad,
CA, USA) supplemented with 10% FCS (Biochrom, Berlin,
Germany). The human gastric adenocarcinoma cell line AGS
(ATCC CRL-1739) was grown in RPMI 1640 medium (Gibco-
Invitrogen, Carlsbad, CA, USA) supplemented with 10% FCS.
For microscopy, cells were seeded on acid-washed glass coverslips.
The GC strains used in this work were derived from N. gonorrhoeae
strain MS11 [47]. Strain P
+GC was selected for observable piliated
phenotype (P
+Opa
2). P
+GC, P
+GCDpilT [48] and non-piliated
Opa57-expressing GC [49] strains were resuspended in cell culture
medium and added to cell monolayers in serum-free medium at a
multiplicity of infection of 100. EPEC strains E2348/69
(O127:H6) and EPEC 2348/69 CVD452, a mutant defective in
type III-dependent secretion, were grown overnight at 37uCi nL B
broth without shaking. The following day cultures were diluted
1:100 in serum free DMEM and grown without shaking under
previously described conditions known to stimulate TTSS
expression for 3.5 h to create so-called preactivated cultures
[50]. Consequently EPEC cultures were added to cell monolayers
for 2 h. Cells were treated with either 100 mM pervanadate (Sigma
Aldrich, St. Louis, MO, USA), 1 mM Cyt D (Sigma Aldrich, St.
Louis, MO, USA) or 100 nM Lat A (Biomol, Hamburg, Germany)
for 30 min, 10 mM PP2 (Calbiochem, San Diego, CA, USA),
10 mM STI571 (LC Labs, Woburn, MA, USA), or 20 mM,
100 mM, and 300 mM NSC23766 (Calbiochem, San Diego, CA,
USA) for 1 h or 50 ng/ml, 100 ng/ml, and 250 ng/ml cell
permeable Rho inhibitor CT04 (Cytoskeleton, Denver, CO, USA)
for 4 h before infection. Experimental treatments had no effect on
bacterial viability.
Gentamicin Protection Assay
Quantification of bacterial binding and entry into host cells was
performed using standard gentamicin-based assays with dilution
plating to recover viable bacteria. Cell confluency at infection time
was 70%. Cells were washed three times in serum-free RPMI 1640
medium prior to infection and incubated in serum-free RPMI
1640 medium (with indicated chemicals) for 30 min. Bacteria were
added to the cells at a multiplicity of infection of 100. Cells were
Figure 5. Vav2 and RhoA act as downstream signaling partners
of Cav1 during P
+GC infection. (A) RhoA activation after P
+GC
infection depends on Cav1 expression. Levels of the active, GTP-bound
state of RhoA are compared between ME-180 shCav1 knockdown cells
and ME-180 shLuciferase control cells during an infection time-course.
Data are mean 6 standard deviation of triplicate wells after normalizing
protein levels. RhoA activity was normalized to uninfected ME-180
shLuciferase cells. (B) Cav1 recruitment does not depend on Vav2
expression or RhoA activation. Cav1 (green) recruitment to attached
P
+GC (red) is observed in ME-180 shLuciferase control cells (blue, upper
left panels), ME-180 shVav2 knockdown cells (blue, upper middle
panels), and Rho inhibitor CT04-treated ME-180 cells (upper right
panels). Recruited Cav1 is indicated by arrows. Efficiency of Vav2
knockdown in ME-180 cells after lentiviral transduction of luciferase
(control) or Vav2 shRNA constructs (lower panel). Scale bar: 20 mm.
Images are representative of three independent experiments.
doi:10.1371/journal.pbio.1000457.g005
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100 mg/ml gentamicin (Sigma Aldrich, St. Louis, MO, USA) was
then added for an additional 2 h to kill extracellular bacteria. Cells
were washed, and 1% saponin (Serva, Heidelberg, Germany) was
added to permeabilize cells followed by plating of appropriate
dilutions of the lysate on GC agar. To quantify adherent bacteria,
lysis with saponin was done prior to gentamicin treatment.
Intracellular gentamicin-protected (Gm
P) bacteria were deter-
mined as a percentage of total cell-associated bacteria. Assays were
conducted in triplicate wells, yielding the given mean and the
standard deviation. Each experiment was repeated at least three
times. Data were tested for significance using Student’s t test.
Representative experiments are shown.
Cloning, Plasmids, and Transfection
The coding region of human caveolin-1 (cav1) was amplified from
total cDNA of the ME-180 cell line and cloned into the expression
vector pcDNA3 (Promega, Madison, WI, USA), which also
encodes an N-terminal HA-tag. For live-cell microscopy, cav1
was cloned into the vector pEGFP-N1 (Invitrogen, Grand Island,
NY, USA). AGS cells were transfected with the vector pcDNA3
alone or the pcDNA3-cav1 construct (Cav1-HA), then stable clones
were isolated and maintained in RPMI supplemented with 10%
FCS and 500 mg/ml G418 (PAA Laboratories, Linz, Austria). The
point mutation Y14F-Cav1-HA was generated by changing
tyrosine 14 of cav1 in Cav1-HA to phenylalanine using the
QuikChange site-directed mutagenesis kit (Stratagene, La Jolla,
CA, USA) according to the manufacturer’s protocol. The accuracy
of the mutation was confirmed by DNA sequencing. Full-length
GFP-Vav2 cloned into pEGFP-C2 was a gift of Dr. La ´szlo ´ Buday
(Semmelweis University, Budapest, Hungary) and truncated Vav2
(consisting of the C-terminal SH3-SH2-SH3 domains of Vav2)
cloned into pcDNA3. FLAG was a gift of Dr. Daniel D. Billadeau
(Mayo Clinic, Rochester, MN, USA). All transfections were
performed using Lipofectamin
TM 2000 (Invitrogen, Grand Island,
NY, USA) according to the manufacturer’s protocol. The cells
were further analyzed 24 h post-transfection.
RNAi
The siRNA duplexes targeting human Cav1 (Cav1A:
GCAGTTGTACCATGCATTA, Cav1B: ATTAAGAGCT-
TCCTGATTG), RhoA (TAGGCTGTAACTACTTTATAA),
Rac1 (ATGCATTTCCTGGAGAATATA), Cdc42 (TTCAG-
CAATGCAGACAATTAA), and firefly luciferase (AACUUACG-
CUGAGUACUUCGA) were purchased from Qiagen (Hilden,
Germany). The siRNA duplexes targeting lamin A (CCT-
GGACTTCCAGAAGAACA) and Vav2 (ON-TARGET Plus
SMART pool containing the following siRNAs: CUGAAAGU-
CUGCCACGAUA, UGGCAGCUGUCUUCAUUAA, GUGG-
GAGGGUCGUCUGGUA, and GCCGCUGGCUCAUCGA-
UUG) were synthesized by Dharmacon Research (Lafayette,
CO, USA). The transfection of siRNAs was carried out using
Hiperfect transfection reagent (Qiagen, Hilden, Germany) ac-
cording to the manufacturer’s instructions. Briefly, ME-180 and
AGS-Cav1 cells were transfected with 50 nM siRNA duplex and
used for experiments 72 h after transfection.
Generation of shRNA Knockdown Cell Lines
shRNA-expressing vectors were constructed by cloning com-
puted shRNA oligonucleotides (Metabion, Martinsried, Germany)
into the pLVTHM vector. The sequences of the targets of the
shRNAs are as follows: human Cav1, 59-CAGCAACAATTTAT-
GAATTGA-39; human Vav2, 59-GCATGACTGAAGATGA-
CAAGA-39; human PLCc1, 59-GGACTTTGATCGCTAT-
CAAGA-39; firefly luciferase, 59-AACTTACGCTGAGTACTT-
CGA-39. All constructs were verified by sequencing. Viruses
carrying the shRNAs were produced by transfecting 293T cells
with the generated pLVTHM constructs together with viral
packaging vectors (psPAX2, pMD2G, kindly provided by D.
Trono, Ecole Polytechnique Fe ´de ´rale de Lausanne, Switzerland)
by calcium phosphate transfection. Viruses were harvested from
the supernatant 48 h after transfection, filtered, and applied to
ME-180 cells for lentiviral infection in the presence of polybrene
(5 mg/ml, Sigma-Aldrich, St. Louis, MO, USA). Pools of GFP-
positive cells were selected and validated for their ability to knock
down protein expression of target genes by more than 70% in
comparison with luciferase control cells.
Microscopy
Cells were grown on coverslips (12 mm diameter) and processed
for immunofluorescence as described previously [51]. Differential
staining of intra- and extracellular bacteria was achieved by
double staining of bacteria, primarily without permeabilization of
cells and subsequently after cell permeabilization. For labeling, the
following antibodies were used: anti-Cav1 (N20, Santa Cruz
Biotechnology, Santa Cruz, CA, USA), rabbit anti-Neisseria
gonorrhoeae (USBiological, Swampscott, MA, USA), and anti-pilus
(m346, monoclonal mouse, generated at the Max Planck Institute
for Infection Biology). All antibodies were used at a 1:100 dilution.
Filamentous actin was detected with Alexa 546-conjugated
phalloidin (Invitrogen, Grand Island, NY, USA). All secondary
antibodies were purchased from Jackson Immuno Research
Laboratories (West Grove, PA, USA). Samples were analyzed by
confocal laser scanning microscopy using a Leica TCS SP
microscope, equipped with an argon/krypton mixed gas laser
source (Leica, Solms, Germany). Image stacks were further
processed using Photoshop (Adobe Systems, San Jose, CA, USA)
or Imaris (Bitplane, Zu ¨rich, Switzerland).
Live-Cell Confocal Microscopy
ME-180 cells were transfected with the described pEGFP-N1-
Cav1 construct and grown in 3.5 cm
2 glass-bottom dishes
(MatTek, Ashland, MA, USA) overnight under standard condi-
tions. Fresh serum-free RPMI without phenol red (Gibco-
Invitrogen, Carlsbad, CA, USA) was added, and cells were placed
in a humidified incubation chamber at 37uC and 5% CO2. Images
were obtained with the VT-Infinity system (Visitron Systems,
Munich, Germany). Briefly, the system consists of an Olympus
IX81 (Olympus, Tokyo, Japan), VT-Infinity galvo scanner
confocal head (Visitron Systems, Munich, Germany), and a
Hamamatsu C9100-02 CCD camera (Hamamatsu Photonics
K.K, Tokyo, Japan). Bright field images were acquired with a
636 phase contrast objective (NA1.25 oil, Olympus, Tokyo,
Japan) and a high-speed shutter system. Fluorescent images were
acquired with a 488 nm laser beam with an intensity of 250 mW
using the 488 nm emission filter set (Chroma Technology,
Brattleboro, VT, USA). Images were collected and processed
using MetaMorph (Universal Imaging Corporation, West Chester,
PA, USA) and Imaris (Bitplane, Zu ¨rich, Switzerland) software.
Immunoprecipitations and Immunoblots
Pervanadate-treated and untreated ME-180 cells were lysed in
16 Cell Lysis Buffer (Cell Signaling, Boston, MA, USA)
containing PhosStop Phosphatase Inhibitor and Complete
TM
Protease Inhibitor (both: Roche Diagnostics, Mannheim, Ger-
many). The lysates were pre-cleared for 4 h with protein G-
agarose beads (Calbiochem, San Diego, CA, USA) and incubated
with 2 mg anti-Cav1 antibody (rabbit, BD Transduction Labora-
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beads were subsequently added for 4 h to precipitate antigen-
antibody complexes. After extensive washing, the precipitate was
eluted by heating to 95uC in SDS loading buffer and the individual
proteins separated by SDS-PAGE. Western blotting was used to
assess the precipitate using the following antibodies: anti-Cav1
(N20, Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-
phospho-Tyr14-Cav1 (clone 56, BD Transduction Laboratories,
Franklin Lakes, NJ, USA) and anti-Vav2 (C64H2, Cell Signaling,
Boston, MA, USA), and HRP-conjugated secondary antibodies
(Amersham Biosciences, Pittsburgh, PA, USA). Western blot was
developed using ECL reagent (ICN Biomedicals, Aurora, OH,
USA). Blots were quantified using ImageJ software (v1.44a).
Peptide Synthesis and Protein Arrays
Fluorescently labeled peptides with sequences corresponding to
residues 5–22 of Cav1 were synthesized, one phosphorylated on
Tyr14 and the other not phosphorylated as previously described
[28], purified to .95% by preparative reverse phase HPLC, and
quality controlled via mass spectrometry and analytical HPLC
(Thermo Electron, Karlsruhe, Germany). Human SH2 and PTB
domains were expressed and purified as previously described [28],
and protein microarrays were fabricated and probed as more
recently reported [52].
Peptide Synthesis and Streptavidin-Agarose Pull-Down
Peptides were designed as 15-mers (residues 7–21 of Cav1)
bearing an N-terminal biotin. Peptides were synthesized as pairs,
one phosphorylated on Tyr14 and the other not phosphorylated,
purified to .95% by preparative reverse phase HPLC, and quality
controlled via mass spectrometry and analytical HPLC (Thermo
Electron, Karlsruhe, Germany). For affinity pull-downs, 10 nmol
of immobilized peptide was added to ,2 mg of cell lysate. ME-
180 cells were lysed in 16Cell Lysis Buffer (Cell Signaling, Boston,
MA, USA) containing 2 mM sodium orthovanadate, as a
phosphatase inhibitor, and Complete
TM Protease Inhibitor (Roche
Diagnostics, Mannheim, Germany). The lysates were pre-cleared
for 1 h with streptavidin agarose beads (Invitrogen, Grand Island,
NY, USA) and equal amounts of lysate were incubated overnight
at 4uC with streptavidin agarose beads, pre-saturated with the
respective biotinylated peptides. After extensive washing, the
streptavidin precipitate was eluted by heating to 95uC in SDS
loading buffer and the individual proteins separated by SDS-
PAGE. Western blotting was used to assess the precipitate using
anti-Vav2 (C64H2, Cell Signaling, Boston, MA, USA) antibody.
Cytoskeletal Preparation
AGS and ME-180 cells (2610
7) were washed with PBS at 4uC
and then incubated in lysis buffer (1 mM EGTA, 4% PEG 6000,
100 mM PIPES pH 6.9, 0.5% Triton X-100) for 5 min at 4uCt o
stabilize the cytoskeleton. Supernatant containing cytoplasmic and
compartmental proteins were removed and the remaining
cytoskeletal proteins washed once, harvested in lysis buffer by
scraping, and pelleted by centrifugation (14,0006g, 5 min). Pellets
were washed once with 1 ml wash buffer (1 mM EGTA, 4% PEG
6000, 100 mM PIPES pH 6.9), then collected in SDS loading
buffer and analyzed by Western blotting.
RhoA Activation Assay
Using an enzyme-linked immunosorbent assay-based RhoA
activation assay kit (Cytoskeleton, Denver, CO, USA) active RhoA
was determined according to the manufacturer’s protocol. Briefly, to
synchronize Rho activity, cell monolayers exhibiting 60% confluency
were grown in culturemedium with 0.5% FCS for an additional 24 h
and then serum-starved for another 16 h. After infection, cells were
lysed at the indicated time points, aliquots snap-frozen in liquid
nitrogen, and the protein concentration determined using Precision
Red Advanced Protein Assay (Cytoskeleton, Denver, CO, USA). Cell
lysate (37.5 mg protein) from each sample was incubated in
microwells coated with the isolated Rhotekin Rho-binding domain.
Active RhoA was subsequently measured using immunodetection
followed by a colorimetric reaction measured by absorbance at
490 nm. Assays were conducted in triplicate microwells, yielding the
given mean and the standard deviation. Data were tested for
significance using Student’s t test.
Immunogold Labeling
Cells were fixed in 2% PFA/1% acrolein in PBS for 2 h at RT.
After washing with PBS, the cells were overlaid with warm gelatine
(10% PBS) and scraped off the plate. After gelling at 4uC, the
specimens were cut into small blocks, post-fixed in 2% PFA, and
infiltrated with a sucrose/PVP solution. Specimens were mounted
on a stub, frozen in liquid nitrogen, and 60 nm sections were
produced using a RMC MTX/CRX cryo-ultramicrotome
(Boeckeler Instruments, Tucson, AZ, USA). Sections were thawed,
blocked, and incubated with anti-Cav1 antibody (rabbit, BD
Transduction Laboratories, Franklin Lakes, NJ, USA). After
washing, bound antibody was detected using anti-rabbit secondary
antibodies coupled to 6 nm colloidal gold. The samples were
analyzed on a Leo 906E transmission electron microscope (Carl
Zeiss, Jena, Germany) equipped with a Morada digital camera
(Silicon Integrated Systems, Hsinchu, Taiwan).
Generation of Anti-Pilus Antibody
P
+GC pili were purified as described previously [53]. Purified
pili were utilized for immunizing BALB/c mice for the generation
of monoclonal antibodies following standard poly-ethylene glycol
(PEG) fusion protocol. Briefly, 6–8-wk-old Balb/c mice were
primed with 50 mg of purified pili in Freund complete adjuvant
followed by two boost injections on day 20 and 40 in Freund
incomplete adjuvant. Spleen cells were fused with P3X63Ag8
myeloma cells. Positive hybridomas were screened by standard
ELISA against purified pili. Anti-pilin antibody producing
hybridomas were subcloned three times by limited dilution.
Supporting Information
Figure S1 The inhibitory effect of Cav1 on P
+GC
internalization is pili-specific and independent of pili
retraction. (A) Attachment of non-piliated P
2Opa57
+GC does not
induce Cav1 (white, middle panel) recruitment 2 h post-infection.
(B) Expression of Cav1 in AGS cells does not inhibit P
2Opa57
+GC
internalization. Mock-transfected AGS cells and AGS-Cav1 cells
wereinfected with P
+GC orP
2Opa57
+GC.(C)Cav1 inhibitsuptake
of the P
+GCDpilT mutant. AGS-Mock and AGS-Cav1 cells were
infected with P
+GC or the P
+GCDpilT mutant. Gentamicin
protection assays were performed 2 h post-infection. Intracellular
gentamicin protected (Gm
P) bacteria were determined as a
percentage of total cell-associated bacteria, which were comparable
forthe differenthostcells.Experimentswereperformedintriplicate.
Error bars indicate mean 6 standard deviation.
Found at: doi:10.1371/journal.pbio.1000457.s001 (0.36 MB TIF)
Figure S2 Tfp-producing EPEC induce Cav1 accumula-
tion and prevent host cell entry. (A) ME-180 cells were
infected with pre-activated cultures of wild-type EPEC strain
E2348/69 and EPEC 2348/69 CVD452, a type III secretion
system (TTSS) defective mutant, for 2 h. Endogenous Cav1
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mutant, whereas the TTSS-preactivated wild type adheres
dispersed and does not trigger Cav1 recruitment. (B) AGS and
AGS-Cav1 cells were infected with E2248/69 wild type and TTSS
CVD452 mutant EPEC. Intracellular gentamicin protected (Gm
P)
bacteria were determined as a percentage of total cell-associated
bacteria. Experiments were performed in triplicate. Error bars
indicate mean 6 standard deviation.
Found at: doi:10.1371/journal.pbio.1000457.s002 (0.89 MB TIF)
Figure S3 Immunogold labeling of Cav1 in ME-180 cells
after infection with P
+GC. Cav1 is 6-nm-gold-labeled (black
arrows). P
+GC are observed as diplococci attached to the cell
membrane (white arrows). Scale bar: 500 nm.
Found at: doi:10.1371/journal.pbio.1000457.s003 (3.63 MB TIF)
Figure S4 Depolymerization of F-actin induces bacterial
internalization and impedes Cav1 recruitment. (A)
Disruption of F-actin filaments (red) with cytochalasin D (CytD)
prevents Cav1 (white, lower panel) recruitment to P
+GC
attachment sites (green). Cellular borders are represented as
yellow outlines. Scale bars: 20 mm. (B) ME-180 cells were treated
with Cyt D or latrunculin A (Lat A), which disrupt actin filaments.
Gentamicin protection assay was performed 2 h post-infection.
Intracellular Gm
P bacteria were determined as a percentage of
total cell-associated bacteria. Ratio of Gm
P P
+GC calculated
relative to untreated control. Experiments were performed in
triplicate. Error bars indicate mean 6 standard deviation.
Found at: doi:10.1371/journal.pbio.1000457.s004 (1.09 MB TIF)
Figure S5 (A) shRNA-mediated downregulation of
PLCc1 in ME-180 cells does not result in P
+GC
internalization. Only extracellular bacteria (yellow-green) are
detected in ME-180 shPLCc1 cells (upper right panels) and ME-
180 shLuciferase control cells (upper left panels). Efficiency of
PLCc1 knockdown in ME-180 cells after lentiviral transduction of
luciferase (control) or PLCc1 shRNA constructs (lower panel).
Scale bar: 20 mm. (B) Knockdown of RhoA but not Rac1 or
Cdc42 in ME-180 results in P
+GC internalization. Intracellular
bacteria (red) are detected in siRhoA-treated cells (upper panel,
lower right image), whereas only extracellular bacteria (yellow-
green) are detected in siCdc42-treated (upper right image), siRac1-
treated (lower left image), and siMock-treated cells (upper left
image). Knockdown efficiencies of Cdc42, Rac1, and RhoA after
siRNA treatment (lower panel; see also Table S2). Scale bar:
20 mm. Data are representative of three independent experiments.
Found at: doi:10.1371/journal.pbio.1000457.s005 (1.15 MB TIF)
Figure S6 Vav2 constructs used in this work. Full-length
GFP-Vav2 cloned into pEGFP-C2 (upper panel) and
truncated Vav2 cloned into pcDNA3.FLAG (lower panel).
Truncated Vav2 only possesses the C-terminal SH3-SH2-SH3
domains of Vav2.
Found at: doi:10.1371/journal.pbio.1000457.s006 (0.17 MB TIF)
Table S1 Synopsis of Rho- and Rac1-inhibitor experi-
ments shows the importance of Rho to prevent P
+GC
uptake in different cell lines. The results of eight experiments
are summarized here. CT04 exhibited dose-dependent uptake
effects in ME-180 as well as HeLa cells in all experiments,
whereas, in general, NSC23766 did not impact P
+GC internal-
ization. To determine uptake rate—i.e., mild, (+); effective, +;
strong, +++—25 or more image stacks of treated and untreated
cells per experiment were analyzed for bacterial uptake and cell
survival.
Found at: doi:10.1371/journal.pbio.1000457.s007 (0.16 MB TIF)
Table S2 Synopsis of siRNA-mediated knockdown ex-
periments of small GTPases Cdc42, Rac1, RhoA under-
scores the importance of RhoA for preventing P
+GC
uptake. Results of five experiments are summarized here. In
three out of four experiments knockdown of RhoA in ME-180 cells
led to increased uptake of P
+GC. By contrast, internalized bacteria
were detected in only one out of four experiments after siRNA
mediated downregulation of Cdc42 and Rac1. To determine
uptake rate—i.e., mild, (+); effective, +; strong, +++—25 or more
image stacks of treated and untreated cells per experiment were
analyzed for bacterial uptake and cell survival.
Found at: doi:10.1371/journal.pbio.1000457.s008 (0.18 MB TIF)
Video S1 Rapid recruitment of Cav1 to sites of P
+GC
adherence. Cav1-GFP (green), time frame 0 to 92 min.
Found at: doi:10.1371/journal.pbio.1000457.s009 (10.36 MB
WMV)
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